Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

References

• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. .
   PubMed Web of Science ®Google Scholar
• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
   PubMed Web of Science ®Google Scholar
• Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol. 2011;146(1):9–15.
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. .
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. .
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. .
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. .
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. .
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20(1):95–104. .
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383–392. .
   PubMed Web of Science ®Google Scholar
• Foulkes AC, Warren RB. Brodalumab in psoriasis: evidence to date and clinical potential. Drugs Context. 2019;8:212570.
   PubMedGoogle Scholar
• Gisondi P, Girolomoni G. Brodalumab in the treatment of chronic plaque psoriasis. Expert Opin Biol Ther. 2020;20(10):1175–1186.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Andersen YMF, A-s H-O, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2020;34(1):39–46. .
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318–1328. .
   PubMed Web of Science ®Google Scholar
• Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci [Internet]. 2019 [ cited 2021 Mar 31];20. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6471628/.
   Google Scholar
• Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3 Br J Dermatol. 2018;179(2):320–328.
   PubMed Web of Science ®Google Scholar
• Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2020;1–5. DOI:https://doi.org/10.1080/09546634.2020.1749546.
   Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790. .
   PubMed Web of Science ®Google Scholar
• Kyntheum | european Medicines Agency [Internet]. [ cited 2021 Apr 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum
   Google Scholar
• Papp KA, Fonjallaz P, Casset-Semanaz F, et al. Analytical approaches to reporting long-term clinical trial data. Curr Med Res Opin. 2008;24(7):2001–2008. .
   PubMed Web of Science ®Google Scholar
• Czarnecka-Operacz M, Polańska A, Klimańska M, et al. Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations. Postepy Dermatol Alergol. 2015;32:426–430.
   PubMed Web of Science ®Google Scholar
• Costa L, Perricone C, Chimenti MS, et al. Switching Between Biological Treatments in Psoriatic Arthritis: a Review of the Evidence. Drugs R D. 2017;17(4):509–522. .
   PubMed Web of Science ®Google Scholar
• Kromer C, Wilsmann-Theis D, Gerdes S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study. J Dermatolog Treat. 2020. p. 1–5.
   Google Scholar
• Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857–859. .
   PubMed Web of Science ®Google Scholar
• Pinter A, Bonnekoh B, Hadshiew IM, et al. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019;12:509–517.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44(4):355–362. .
   PubMed Web of Science ®Google Scholar
• Munera-Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol. 2019;33(1):e40–e42. .
   PubMed Web of Science ®Google Scholar
• Napolitano M, Megna M, Fabbrocini G, et al. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition. Br J Dermatol. 2019;181(3):604–606. .
   PubMed Web of Science ®Google Scholar
• Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020;20(6):665–672. .
   PubMed Web of Science ®Google Scholar
• Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatol (Basel). 2008;217(4):365–373.
   Google Scholar
• Mourad A, Straube S, Armijo‐Olivo S, et al. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2019;181(3):450–458. .
   PubMed Web of Science ®Google Scholar
• Kisielnicka A, Szczerkowska-Dobosz A, Nowicki RJ. The influence of body weight of patients with chronic plaque psoriasis on biological treatment response. Postepy Dermatol Alergol. 2020;37(2):168–173.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Raimondo A, Lembo S, et al. Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity. Expert Rev Clin Immunol. 2016;12(12):1299–1308. .
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Perino F, et al. Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis. J Dermatolog Treat. 2017;28(4):299–303. .
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. .
   PubMed Web of Science ®Google Scholar
• Naik GS, Ming WK, Magodoro IM, et al. Th17 Inhibitors in Active Psoriatic Arthritis: a Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Dermatology. 2017;233(5):366–377. .
   PubMed Web of Science ®Google Scholar
• Rusta-Sallehy S, Gooderham M, Papp K. Brodalumab: a Review of Safety. Skin Therapy Lett. 2018;23(2):1–3.
   PubMedGoogle Scholar
• Galluzzo M, D’Adamio S, Campione E, et al. A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab. In: J Dermatolog Treat. 2018. p. 1–11.
   Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751. .
   PubMed Web of Science ®Google Scholar
• Xing X, Liang Y, Sarkar MK, et al. IL-17 Responses Are the Dominant Inflammatory Signal Linking Inverse, Erythrodermic, and Chronic Plaque Psoriasis. J Invest Dermatol. 2016;136(12):2498–2501. .
   PubMed Web of Science ®Google Scholar
• Masson Regnault M, Konstantinou M-P, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31(9):1491–1496. .
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037–1048. .
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Wu JJ, et al. Two-Year US Pharmacovigilance Report on Brodalumab. Dermatol Ther (Heidelb). 2021;11(1):173–180. .
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: a Meta-analysis. JAMA Dermatol. 2020;156(3):258–269. .
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. Am J Clin Dermatol. 2019;20(6):863–871. .
   PubMed Web of Science ®Google Scholar
• Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352–359. .
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Dapavo P, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35(3):693–700. .
   PubMed Web of Science ®Google Scholar
• Facheris P, Valenti M, Pavia G, et al. Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020;33(3):e13403.
   PubMed Web of Science ®Google Scholar